Corporate Advisory Consulting AgreementAdvisory Consulting Agreement • March 16th, 2021 • Save Foods Inc. • Agricultural chemicals • New York
This Corporate Advisory Consulting Agreement (this “Agreement”), is made as of August 30, 2017, between Save Foods, Inc., a Delaware corporation, having its principal place of business located at C.O: Earthbound LLC, 156 Fifth Avenue, Floor 10, New York, NY 10010-7751156 USA (the “Company”) and Goldmed Ltd. an cornpany organized under the laws of the state of Israel, having an address Herzl Rosenblum St 6 Tel Aviv, Israel under the control of Prof. Benad Goldwassr (the “Consultant”), the Company and the Consultant are sometimes referred to individually, as a “Party” and collectively, as the “Parties.”
AMENDMENT TO ADVISORY CONSULTING AGREEMENTAdvisory Consulting Agreement • November 1st, 2006 • Minrad International, Inc. • Pharmaceutical preparations
INTERNATIONAL CAPITAL ADVISORY INC. (“ICA”) and MINRAD INC. (“Minrad”) hereby enter into this Amendment to Advisory Consulting Agreement (the “Amendment”) and agree as follows:
AMENDED AND RESTATED ADVISORY CONSULTING AGREEMENT Dated as of July 13, 2007Advisory Consulting Agreement • October 11th, 2007 • Southridge Technology Group, Inc. • Services-computer programming services
This Amended and Restated Advisory Consulting Agreement (this “Agreement”) amends and restates the prior Advisory Consulting Agreement, dated as of September 18, 2006, by and between in its entirety RxElite (“RxElite” or the “Company”) and International Capital Advisory Inc. (“ICA”).
ADVISORY CONSULTING AGREEMENTAdvisory Consulting Agreement • January 7th, 2019 • Cure Pharmaceutical Holding Corp. • Plastics, foil & coated paper bags • California
This Advisory Board Consulting Agreement (the “Agreement”) is made and effective as of December 14, 2018 (the “Effective Date”), by and between CURE Pharmaceutical Holding Corp., a Nevada corporation (the “Company”) and Michael J. Willner, an individual (the “Consultant” and together with the Company, the “Parties”).
AMENDMENT NO. 1 TO ADVISORY CONSULTING AGREEMENTAdvisory Consulting Agreement • December 31st, 2018 • Neurotrope, Inc. • Pharmaceutical preparations • New York
AMENDMENT NO. 1 TO ADVISORY CONSULTING AGREEMENT (the “Amendment”) dated as of December 21, 2018, by and between KATALYST SECURITIES LLC, a broker dealer registered with the Financial Industry Regulatory Authority (“FINRA”) (“Katalyst”) and NEUROTROPE, INC., a publicly traded company incorporated in the State of Nevada (the “Company”).
AMENDMENT NO. 1 TO ADVISORY CONSULTING AGREEMENTAdvisory Consulting Agreement • December 31st, 2018 • Neurotrope, Inc. • Pharmaceutical preparations • New York
AMENDMENT NO. 1 TO ADVISORY CONSULTING AGREEMENT (the “Amendment”) dated as of December 31, 2018, by and between MAXIM GROUP LLC, a broker dealer registered with the Financial Industry Regulatory Authority (“FINRA”) (“Maxim”) and NEUROTROPE, INC., a publicly traded company incorporated in the State of Nevada (the “Company”).
ADVISORY CONSULTING AGREEMENTAdvisory Consulting Agreement • January 23rd, 2020 • Neurotrope, Inc. • Pharmaceutical preparations • New York
ADVISORY CONSULTING AGREEMENT (the “Agreement”) dated as of January 22, 2020 (the “Agreement”) by and between KATALYST SECURITIES LLC, a broker dealer registered with the Financial Industry Regulatory Authority (“FINRA”) (“Katalyst”) and NEUROTROPE, INC., a publicly traded company incorporated in the State of Nevada (the “Company”).
